Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 206.54

+3.2%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Machaon who wrote (20624)	5/12/1998 9:58:00 PM
From: Andrew H	Read Replies (1) of 32384

>> Is the glass half full, or half empty? We could say that a significant percentage of the patients, 63%, did not have significant side effects. That's not bad. Plus, if they get good results from the 63% group, there is always the possibility of dosage adjustments, etc. as the product evolves, to deal with the 37% bad side effect problem.<< The point has been well made that the 37% was most likely not representative of the general target population. Only the most advanced cases were used. Actually though, 37% having to stop the treatment under normal circumstances would be pretty bad, IMO. >>I've got a question. When the FDA gives a product "fast track" designation, does that mean that the FDA has taken a fairly good look at the product?<< Its my understanding that fast tracking is often done for drugs that treat fatal or especially grisly diseases, especially when the treatment shows promise of helping individuals who could not previously be helped. Means that there is considerable urgency.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next